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Abstract
Familial hypercholesterolaemia (FH) is a monogenic disorder of low-density lipoprotein (LDL) metabolism. It is characterised 
by markedly elevated LDL cholesterol, autosomal dominant inheritance, premature cardiovascular disease and tendon 
xanthomata. FH is a genetically heterogeneous disorder, but the most common underlying molecular cause is mutation of 
the LDL receptor gene. The worldwide prevalence of FH is 1:500. South Africa has three founder populations in which the 
prevalence of FH may be as high as 1:70. FH is diagnosed clinically, but the diagnosis can be confirmed by DNA analysis. 
DNA testing cannot always identify the causative mutation because there are several genes to examine and more than 1 500 
different mutations have been identified in the LDL receptor alone. Statins are the treatment of choice for patients with FH. 
Ezetimibe or cholestyramine can be added if additional LDL lowering is required, or if patients are unable to tolerate high 
statin doses. 
 Peer reviewed. Reprinted from S Afr Fam Pract 2011;53(1):11-18 with permission
Introduction
Familial hypercholesterolaemia (FH) is probably the most 
common monogenic disorder that the general practitioner is 
likely to encounter. Worldwide the prevalence is estimated 
to be around 1:500, but in populations with a founder 
effect (see below), the prevalence may be as high as 
1:70.1 FH, however, remains seriously underdiagnosed and 
undertreated. In the UK, it is estimated that more than 80% 
of FH patients remain undiagnosed.2 Early detection and 
treatment of FH may save many lives because up to 30% of 
patients do not survive an initial myocardial infarction (MI). 
Although there are no accurate South African statistics, 
the local situation is not likely to be much different. What 
distinguishes South Africa from the UK is that, as a result of 
founder effects, there are three ethnic communities in which 
FH is highly prevalent. FH is thus even more relevant in 
South Africa. The challenge to all of us is not only to identify 
and treat the index patient, but also to screen families 
whenever possible. 
Familial hypercholesterolaemia 
FH is a clinically defined syndrome. The key diagnostic 
elements are a family history of autosomal dominant low-
density lipoprotein (LDL) hypercholesterolaemia, premature 
cardiovascular disease and tendon xanthomata. FH is a 
monogenic disorder; mutation of a single gene is sufficient 
to cause the phenotype. Thus far, four genes that cause FH 
have been identified. The diagnosis of FH is clinical, but the 
causal gene can only be identified by genetic testing. 
FH phenotypes
Some of the genes linked to FH display a gene dose effect, 
with a much more severe phenotype (homozygous FH 
[hoFH]) when both alleles of the gene are mutated (‘double 
dose’). Heterozygous FH (heFH) results from a single 
mutated allele (‘single dose’) and is far more common than 
hoFH. 
Heterozygous FH
The LDL cholesterol (LDLC) in heFH is usually between 
5 and 12 mmol/L. At the Groote Schuur Hospital (GSH) 
Lipid Clinic, the median LDLC in untreated patients with 
definite FH was 6.95 mmol/L but, as Figure 1 shows, there 
is a wide range of LDLC values. The prevalence of tendon 
xanthomata and other physical stigmata of hyperlipidaemia 
increases with age (Figure 2). About 93% of patients will 
develop tendon xanthomata (Figure 3) during their lifetime.3 
HeFH is associated with a markedly increased risk of death 
from ischaemic heart disease (IHD). The increased risk of 
death is highest in young patients. Data from the Simon 
Broome FH Registry, collected mainly in the pre-statin era, 
show a standardised mortality ratio (SMR) for IHD in the 
20–39-year-old cohort of 9 686 (95% confidence interval 
3 670–21 800).4 Comparing this with the SMR of 100 in a 
control population reveals just how enormous the increased 
risk associated with FH is.  
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Homozygous FH
The LDLC in hoFH is usually > 12 mmol/L, and often 
significantly higher. Skin and tendon xanthomata usually 
develop before the age of 10 years. Planar xanthomata 
(Figure 4) and interdigital xanthomata (Figure 5) in infants 
and toddlers often are the first clue to the diagnosis. IHD, 
which may be fatal, is common in children or adolescents. 
Lipid deposition in the ascending aorta often causes 
supravalvular aortic stenosis that may require aortic valve 
and root replacement. 
Genes linked to FH
The primary lipid abnormality in FH is marked elevation 
of LDLC. LDL is the primary atherogenic lipoprotein in 
humans, and also transports the bulk of plasma cholesterol. 
Most plasma LDL is generated in the circulation from 
hepatically secreted very low-density lipoproteins (VLDL) 
following lipolytic processing. Most cells can take up LDL if 
they require cholesterol, but hepatic LDL uptake determines 
plasma LDL concentration. The liver removes LDL from the 
circulation via the LDL receptor (LDLR) and malfunction of 
Figure 3: Achilles tendon xanthomata in a patient with heterozygous FH. 
The Achilles tendons are markedly thickened and irregular.
Figure 4: Planar xanthoma in a patient with homozygous FH.
There are multiple cutaneous deposits of cholesterol in this patient. 
Figure 5: Interdigital xanthomata in a patient with homozygous FH.  
Interdigital xanthomata are pathognomonic of homozygous familial 
hypercholesterolaemia.
Figure 1: LDLC distribution in untreated FH patients at the GSH Lipid Clinic.
The median LDLC is 6.95 mmol/L with a mean LDLC of 7.22 mmol/L.
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Figure 2: Cumulative prevalence of physical signs in adult FH patients at the
GSH Lipid Clinic. The prevalence of arcus cornealis increases almost linearly
with age while the prevalence of tendon xanthomata increases most rapidly
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this system with defective clearance of LDL causes LDL 
to accumulate. All of the genes that have thus far been 
linked to FH interfere with LDL clearance, either directly or 
indirectly.
LDLR
The LDLR was the first gene linked to FH. Mutations of 
the LDLR are by far the most common molecular cause of 
FH. Brown and Goldstein discovered the LDLR in a series 
of groundbreaking experiments and were awarded the 
1985 Nobel Prize for their work. Their discovery was not 
only crucial to understanding FH, but was also one of the 
first demonstrations of receptor-mediated endocytosis, a 
process critical to understanding cell biology.5
The LDLR is located on chromosome 19 and has 18 exons. 
Thus far, more than 1  500 different mutations have been 
identified in the LDLR. At the GSH Lipid Clinic, 64 different 
LDLR mutations have been documented thus far, and many 
more are likely to be found by systematic screening of our 
cohort of FH patients for LDLR mutations. 
Founder populations are characterised by a high prevalence 
of FH, with one or a few LDLR mutations explaining a large 
proportion of cases. South Africa has three populations in 
which founder effects are seen. The most common LDLR 
mutations (the amino acid change in the LDL protein is 
indicated) are listed in brackets:
• White South Africans of Afrikaner descent (D206E, 
V408M and D154N).
• Jewish South Africans of Lithuanian descent (deletion 
G197).
• Indian South Africans of Gujerati descent (P664L).
Apolipoprotein B100
Each LDL particle contains one apolipoprotein B100 (apo 
B100) molecule, which forms the structural backbone of the 
lipoprotein. Binding of LDL to the LDLR occurs exclusively 
via apo B100. Mutations in the binding region of apo B100 
decrease its affinity for the LDLR and reduce LDL clearance. 
There is no local founder effect for apo B100 mutations and 
less than 1% of patients with a clinical diagnosis of FH at 
the GSH Lipid Clinic have identified apo B100 mutations. 
The most common apo B100 mutation (R3500Q) is thought 
to have originated in central Germany, with its subsequent 
distribution tracking the migration of Celtic tribes.6 FH due 
to mutations in apo B100 is sometimes also called familial 
defective binding apo B100 (FDB).
PCSK9
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a 
relatively recently discovered protein that down-regulates 
LDLR activity.7 PCSK9 differs from the genes described 
above in that both gain-of-function and loss-of-function 
mutations have been described. Mutations that increase 
PCSK9 activity impair LDLR activity and cause FH. Loss-
of-function mutations are associated with low LDLC levels 
and low rates of cardiovascular disease.8 In Cape Town, 
one family with FH secondary to a PCSK9 gain-of-function 
mutation has been found. 
Autosomal recessive hypercholesterolaemia
The autosomal recessive hypercholesterolaemia (ARH) 
protein is an adaptor protein that is critical to the functioning 
of the LDLR in hepatocytes. Heterozygous mutations in 
ARH are not associated with hypercholesterolaemia, but 
homozygous mutations lead to a hoFH phenotype. There 
is currently one known ARH patient in South Africa. Most of 
the patients diagnosed worldwide with ARH originate from 
Sardinia.9 
Clinical genetics of FH
LDLR mutations
The inheritance of FH is autosomal dominant. Mutation of 
one of the two alleles of the LDLR (heterozygous state) is 
sufficient to cause the phenotype. Patients with two mutated 
alleles have hoFH and a much more severe phenotype. The 
risk of inheriting the disorder from the affected parent is 
50% for each child if the parent has heFH. If both partners 
have heFH, there is a 25% chance of having a child with 
hoFH, a 50% chance that the child will be heterozygous 
and a 25% chance that the child will not have inherited 
hypercholesterolaemia. The children of a homozygous 
parent are obligate heterozygotes, as they can only inherit a 
mutated allele from their affected parent. Should the other 
parent be a heterozygote, the risk of homozygosity for the 
children is 50%. 
The disorder does not skip generations and is not sex 
linked; men and women are affected with equal frequency. 
Some common misconceptions about the genetics of FH 
include the following:
• Men are affected more frequently than women. 
- As cardiovascular disease occurs earlier in men than 
women, it is often more dramatically premature, 
creating the impression that FH is more common in 
men.
• A child will only inherit the condition if he or she is of the 
same gender as the affected parent. 
- This is a misunderstanding of the genetics of FH; 
there is no sex-linked inheritance. 
• If a couple, in which one partner has heFH, has two 
affected children, the third child is likely to be unaffected. 
- Although statistically 50% of the children of this 
couple will be affected, each conception ‘flips the 
genetic coin’ afresh, unaffected by previous results. 
The chance that the third child will be a heterozygote 
therefore remains 50%. 
• Patients that do not come from founder populations do 
not have/cannot have FH. The diagnosis of FH is, for 
instance, often not considered in black South Africans as 
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FH is viewed as a disease exclusive to white Afrikaners.
- There is no founder effect in black South Africans, but 
FH still occurs at the worldwide prevalence of 1:500. 
Apo B100 mutations
This is also an autosomal dominant condition and the same 
considerations as for LDLR mutations apply, except that 
there is no gene dose effect and patients with two mutated 
alleles (homozygosity) do not have a much more severe 
phenotype than heterozygous patients.10 This is likely due 
to increased clearance of LDL precursor lipoproteins by the 
up-regulated LDLR.
PCSK9 
The inheritance of PCSK9 is also autosomal dominant. 
Homozygosity for gain-of-function hypercholesterolaemic 
mutations has not been described thus far. Homozygous 
or compound heterozygote loss-of-function mutations 
are associated with very low LDLC without other adverse 
effects.11
ARH 
ARH is a recessive condition. Heterozygotes are clinically 
normal and homozygotes have the hoFH phenotype. 
Diagnosing FH
Family history
Obtaining a detailed family history takes a few minutes, 
but the time invested is definitely worthwhile. A well-taken 
family history is very useful in elucidating the inheritance 
pattern of hyperlipidaemia and identifying other family 
members potentially at risk. 
The easiest way to record the family history is by drawing 
a family tree (see Figure 6 for an example), which should 
include as many generations as possible. Most patients 
can provide information on at least three generations (index 
patient, parents and grandparents), and a fourth generation 
can be added if the index patient has children. As much as 
possible, relevant information is then added to the family 
tree. When FH is the primary focus, important details would 
include the following: 
• Surnames and maiden names (women);
• Geographical and ethnic origin;
• Age and cause of death for all deceased family members;
• Lipid values or treatment for hypercholesterolaemia;
• Major medical diagnoses in family members;
• Age at which cardiovascular disease, if present, first 
became manifest.
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Figure 6: Family tree of an FH family.
The index patient was referred for assessment of cardiac transplantation, as he had developed severe heart failure following multiple MI. The family tree shows 
that there are still multiple unscreened relatives, including the children of the index patient.
The index patient is indicated with an arrow. Men are represented by squares and women by circles. Deceased individuals are indicated by a diagonal line drawn 
through the symbol. Half-shading is used to indicate proven or inferred heFH
Note: This is an original family tree that has been redrawn to increase clarity. Names have been removed to ensure confidentiality and minor edits have been made for illustrative 
purposes. 
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Documenting surnames and maiden names often allows one 
to link patients into families with FH already known to the 
clinic. In many cases, patients are not aware of the link and 
may even meet ‘new’ relatives in the waiting room. Details 
on geographic and ethnic origin are useful in identifying 
whether there are any potential links to founder populations. 
Medical and lipid details are useful in judging the likelihood 
of the family member having FH. Because cardiovascular 
disease remains the most common cause of death, simply 
stating that there is a ‘family history of cardiovascular 
disease’ is of little diagnostic value. This would equally 
apply if the grandfather died of a an MI when he was 86 
years old, or if the father had his first MI at age 28 and died 
at 32. The latter history of premature cardiovascular disease 
is clearly more relevant. Premature cardiovascular disease 
is somewhat arbitrarily defined as cardiovascular disease 
occurring before 55 in men, and before 60 in women. The 
amount and accuracy of detail that patients can provide 
obviously varies widely, but even a relatively sparse family 
tree may be helpful. 
Clinical examination
Tendon xanthomata
The tendon xanthoma is the cardinal physical sign of 
familial hypercholesterolaemia. Tendon xanthomata result 
from deposition of lipoproteins within tendons following 
microvascular trauma. The Achilles tendon is the most 
commonly affected tendon, followed by the extensor 
tendons of the hand, but xanthomata are occasionally found 
in other tendons. Large Achilles xanthomata may be obvious 
on inspection, but smaller xanthomata are best detected by 
palpation. Occasionally one may not feel a discrete nodule, 
but rather a more general thickening and rounding of the 
usually elliptical Achilles tendon. In the hands, extensor 
tendon xanthomata are firm, non-compressible nodules 
that move with the tendon. Many patients with FH can recall 
episodes of Achilles tendonitis, often after unaccustomed 
exercise.  
Tendon xanthomata are always pathological and clinically 
important. In clinical practice the vast majority of patients 
with tendon xanthomata will have FH. Patients with 
dysbetalipoproteinaemia (type III hyperlipidaemia), a genetic 
disorder of remnant lipoprotein metabolism, occasionally 
have tendon xanthomata. Dysbetalipoproteinaemic patients 
have a severe mixed hyperlipidaemia, and the ratio of 
total cholesterol to triglycerides often approximates 2:1. 
Phytosterolaemia and cerebrotendinous xanthomatosis are 
two very rare disorders of sterol metabolism in which large 
tendon xanthomata are a prominent feature. Patients with 
unexplained tendon xanthomata should be referred to a 
lipid clinic for further investigation. 
Arcus cornealis
As a clinical sign, arcus cornealis is of limited usefulness. 
It is not specific for FH and the prevalence rises with age, 
even in those without hyperlipidaemia. Arcus cornealis in a 
patient under 45 is suggestive of significant hyperlipidaemia. 
Xanthelasma
Xanthelasma are not diagnostically useful, but often are of 
major cosmetic concern. Many patients with xanthelasma 
do not have significant hyperlipidaemia. 
Diagnostic assessment
The diagnosis of FH is easy in hypercholesterolaemic 
individuals with a positive family history of autosomal 
dominant hypercholesterolaemia and premature 
cardiovascular disease who have tendon xanthomata on 
examination. Many patients, however, do not present with 
a ‘full house’ of clinical features, and diagnosis can then be 
more challenging. Diagnostic problems may, for instance, 
occur in younger patients who have not yet developed 
tendon xanthomata, in patients with incomplete family 
information, when premature death from other causes 
prevents cardiovascular disease from manifesting in the 
family, or when paternity is doubtful. 
Several groups have developed clinical diagnostic tools 
for use in FH. These tools include the Dutch Lipid Clinics 
Network criteria, the MedPed criteria and the Simon 
Broome Registry criteria. These diagnostic tools all evaluate 
the family history, the presence of tendon xanthomata, and 
laboratory results to assess the likelihood of the patient’s 
having FH. The Dutch Lipid Clinics Network criteria, 
illustrated in Table I, classify patients as having ‘definite’, 
‘probable’ or ‘possible’ FH.12





Premature cardiovascular disease ( M < 55; F < 60) 1
LDLC > 95th centile 
for age and sex
Adult relative 1
Relative < 18 years old 2
Tendon xanthomata or arcus < 45 2
Clinical
Vascular disease
Patient has premature IHD 2
Patient has premature 




Tendon xanthoma found 6
Arcus cornealis present 




LDLC > 8.5 mmol/L 8
LDLC: 6.5–8.4 mmol/L 5
LDLC: 5.0–6.4 mmol/L 3
LDLC: 4.0–4.9 mmol/L 1
DNA analysis
DNA testing confirms 
pathogenic mutation in LDLR, 
or other gene related to heFH
8
Scoring
> 8 points: definite FH
6–8 points: probable FH
3–5 points: possible FH
Note: These criteria apply to adults and not children. 
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Differential diagnosis 
Familial combined hyperlipidaemia (FCH) is the most 
common genetic differential diagnosis. FCH is also an 
autosomal dominant disorder, but the underlying genetic 
abnormality has not yet been conclusively identified. The 
prevalence may be as high as 1:100. The phenotype is 
characterised by an excess of apo B-containing lipoproteins. 
This may manifest as excessive LDL, excessive VLDL or 
a combination of both. Tendon xanthomata do not occur. 
There is no diagnostic test for FCH, and definite diagnosis 
requires lipid information from multiple family members. 
Secondary causes of severe LDL hypercholesterolaemia 
include hypothyroidism, nephrotic syndrome, obstructive 
liver disease and drugs. Secondary causes should always 
be excluded. 
Genetic testing
The initial diagnosis of FH remains clinical, but genetic 
testing can identify the affected gene and pinpoint the 
mutation. It is not essential to do genetic testing, as patients 
can be managed clinically. Identification of a pathogenic 
mutation in an FH gene confirms the diagnosis. Once the 
mutation has been identified in a family, it is easy to screen 
other members of the family with DNA testing. Prenatal 
diagnosis of hoFH is also possible in at-risk families with 
known mutations. 
Genetic testing is, however, not without problems. In 
patients with heFH there are three genes to screen, with 
more than 1 500 possible mutations in the LDLR alone. A 
‘negative’ genetic test therefore does not mean that the 
patient does not have FH; the mutation may simply not have 
been tested for. Most laboratories will only test for a few 
common mutations, although some European laboratories 
now routinely sequence the LDLR if no common mutations 
are found in the initial screening phase. Such an approach 
requires the state to commit significant resources towards 
identification and treatment of FH. There is little state or 
medical funder support in South Africa for identifying and 
treating FH. Genetic testing should ideally be done at lipid 
clinics where there is close co-operation between clinicians 
and the laboratory. 
Management
Managing FH requires the clinician to pay attention to two 
distinct aspects: individual patient management to reduce 
cardiovascular risk and management of the family at risk. 
Treating the individual
The risk of cardiovascular disease in FH patients is many 
times higher than in the population average. Premature 
cardiovascular disease is common even in the absence of 
other risk factors. Cardiovascular risk in FH is largely driven 
by the very high LDLC, and treatment strategies thus focus 
on LDLC reduction and avoidance or management of other 
risk factors. 
All patients with FH should be given advice on a healthy 
lifestyle. Regular exercise should be encouraged and 
smoking strongly discouraged. There is no set ‘diet’ 
for patients with FH; instead, patients should receive 
education about the principles of a healthy diet and how to 
preferentially choose healthy foods. A dietitian will evaluate 
the patient’s diet, provide education and indicate healthy 
choices amongst the foods routinely consumed by the 
patient. Ideally the entire family, including family members 
that do not have FH, should adopt healthy eating habits. All 
will benefit and nobody will feel disadvantaged by having 
to eat ‘special’ food. Occasionally one encounters ‘dietary 
nihilism’ amongst patients with FH: “My cholesterol is 
genetic and diet will not make a difference.” Although diet 
will not normalise the LDLC in FH, it can often lower LDLC 
by about 1.0 to 1.5 mmol/L. A healthy diet has many other 
additional health benefits that are independent of LDLC 
lowering. Omega-3 fatty acid supplementation has, for 
instance, been shown to reduce the risk of death in patients 
post-MI.13
Patients with FH are generally asymptomatic until 
atherosclerotic complications set in. Drug treatment can 
thus not improve their sense of well-being; if anything, they 
may feel less well if they develop side-effects. Stopping 
the drug does not provoke symptoms, as for instance in a 
patient with asthma who stops using inhalers, yet lifelong 
compliance is necessary. Achieving long-term dietary and 
drug adherence can thus be quite challenging. Strategies 
that may improve adherence include patient education, 
regular review of therapy and supporting patients when 
medical funds decline requests for appropriate therapy. 
Risk assessment
Conventional cardiovascular risk assessment (Framingham) 
is inappropriate and dangerous in FH. Risk assessment 
algorithms are designed to cater for the majority of the 
population with risk factors in the usual range; they do 
not work when a single risk factor, such as LDLC in FH, 
is markedly elevated. See Box 1 for an example of how 
inappropriate risk calculation in FH is. Unfortunately, 
many medical funds still request risk calculation, although 
the prescribed minimum benefit (PMB) algorithm for 
hyperlipidaemia makes provision for FH treatment without 
risk calculation. Patients are, however, still being denied 
treatment to which they are entitled. Sometimes, this is 
intransigence on the part of the medical aid, but at times 
medical practitioners also fail to identify and label FH as 
such and funding requests are thus declined. 
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All FH patients require treatment; the question for the 
individual is not whether to treat but when to start treatment. 
In adults, treatment should generally be initiated at diagnosis 
or very soon thereafter.
Statins have been shown to be safe in children in short-
term studies, but no studies have addressed the question 
of the optimal age of treatment initiation. The decision to 
treat should be individualised, based on the child’s family 
history (age of onset of IHD in family), the LDLC and the 
presence of other risk factors.2 One also needs to consider 
the attitude of the child and parents to treatment and the 
likelihood that treatment will actually be taken. Depending 
on the circumstances, one may thus recommend starting 
treatment before the age of 10 in some, while waiting till 
late adolescence in others. Referring the family for an 
assessment at a lipid clinic can be helpful in deciding on 
treatment. Once the decision to treat has been made, 
statins rather than bile acid sequestrants (BAS, e.g. 
cholestyramine) should be prescribed. The latter used to 
be recommended as initial treatment for children because 
they are not absorbed systemically, but cholestyramine is 
less effective than statins and frequently causes nausea, 
bloating and constipation. This leads to poor compliance, 
and the child may develop an aversion to doctors and lipid-
lowering treatment. 
In general, there is no reason to advise against pregnancy 
or breastfeeding in women with FH. Statins are, however, 
not licensed for use during pregnancy and contraception 
must be discussed with all potentially child-bearing female 
patients. Contraception should be reviewed at each follow-
up visit. The contraceptive choice is based on standard 
indications and contraindications. Patients that wish to 
conceive should first stop lipid-lowering therapy and can 
then discontinue contraception two to three months later. 
Although BAS are theoretically safe during pregnancy, 
patients are generally not prescribed any lipid-lowering 
therapy while pregnant or breastfeeding. There is therefore 
also no need to monitor lipid levels routinely during 
pregnancy. In fact, documenting the physiological rise of 
LDLC during pregnancy may cause unnecessary anxiety. 
Statin therapy can resume once the infant has been weaned 
and contraception has been restarted. 
Women who conceive inadvertently while on statins should 
discontinue the statin immediately and be referred for 
detailed foetal assessment. There are limited data on the 
safety of statins in pregnancy, but the available data do not 
suggest that the risk of malformations is markedly increased 
or that there is a specific pattern of foetal malformation with 
statin exposure.2 
LDLC-lowering therapy
Statins are the lipid-lowering drugs of choice in patients 
with FH. They reduce LDLC very effectively and their safety 
and efficacy have been well documented. Because LDLC 
is so markedly elevated in FH, it is often difficult to reach 
the LDLC targets recommended by guidelines. However, 
one should aim to reduce LDLC by at least 50%.2 This can 
usually only be achieved by using high-potency statins, 
such as atorvastatin or rosuvastatin. The top doses are 
frequently required, because doubling the statin dose only 
achieves a further 6% LDLC reduction. 
Ezetimibe is a cholesterol absorption inhibitor that lowers 
LDLC by about 18–20% as monotherapy. The LDLC 
lowering achieved with ezetimibe is additive to that of 
statins. Ezetimibe is generally well tolerated and is thus 
useful as add-on therapy when LDLC levels remain high, 
despite maximal or maximally tolerated statin doses. 
BAS can lower LDLC by up to 25%, but their usefulness is 
limited by their poor tolerability. They may also interfere with 
the absorption of other medications and have largely been 
superseded by ezetimibe, which has become the drug of 
choice when additional LDLC lowering is required. 
Fibrates and nicotinic acid may be useful in carefully 
selected patients with additional lipid abnormalities, such 
as high triglycerides or low HDLC. The combination of a 
high-dose statin and a fibrate or nicotinic acid should only 
be initiated at specialist level.2
Patients with hoFH should be treated at lipid clinics. 
Conventional lipid-lowering therapy is only modestly 
Box 1: Framingham risk equation and FH
Mr Smith attends your practice for risk evaluation. He is 
feeling well and has no prior history of cardiovascular disease 
or diabetes. He is on no medication. He is worried because 
his father died of a MI at age 44 and he is now approaching 
that age. His details are as follows:
Age: 40 years 
Blood pressure: 144/82 mmHg (not on treatment) 
Total cholesterol: 10.3 mmol/L 
HDL cholesterol: 1.2 mmol/L 
Smoking status: Never smoked
You diagnose hypercholesterolaemia and complete the 
application form of his medical aid for chronic benefits. 
The Framingham risk is 6% for the next 10 years and the 
medical aid informs Mr Smith that he does not qualify for 
lipid-lowering medication. 
The average age of death in untreated men with heFH is 43 
years and Mr Smith clearly does need to be treated. The 
Framingham equation should never have been requested or 
performed. You inform the medical aid that Mr Smith has FH 
and must be treated and indicate that you are willing to take 
up the matter with higher authorities if treatment continues 
to be denied. 
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effective in hoFH, but some newer drugs are showing very 
promising results in clinical trials.
Treating the family
The pedigree is the starting point for family evaluation. The 
recommended screening strategy for FH is cascade testing: 
using the index patient as a starting point, other potentially 
affected relatives are screened. Screening is best done by 
genetic testing if the mutation is known. LDLC is used if the 
mutation has not been identified.2 LDLC screening is easier 
and cheaper than DNA screening, but will misclassify some 
individuals with indeterminate LDLC values. 
Screening a family successfully requires their co-operation. 
This is unfortunately not always given. Some of the problems 
encountered during screening include the following:
• Patients lose contact with their families: “Don’t know.”
• Contact may have been broken off deliberately: “Not 
talking to each other.”
• Patients may not want other family members to know 
that they have hypercholesterolaemia: “Don’t tell.”
• Family members may not want to face the possibility that 
they have an inherited disorder: “Not interested.” 
Currently there is no systematic screening strategy for 
FH in South Africa and screening is opportunistic. The 
Netherlands has a highly developed screening system 
based on DNA testing and a central, nationwide register. 
Many previously undiagnosed patients have been identified 
using this approach. 
Starting a family
The potential risk of having a child with hoFH should be 
discussed with all heFH patients planning to start a family. 
The risk is particularly high if the partner originates from a 
founder population. A heterozygote that has a child with a 
partner from a founder population has a 1:400 chance of 
having a homozygous child, based on a mutation prevalence 
of 1:100 in the founder community and a 1:4 chance that 
two heterozygotes will have a homozygous child. This is a 
substantial risk that one should not ignore.
Conclusion
The diagnosis of FH should be considered in all patients 
with severe LDLC hypercholesterolaemia not attributable 
to other causes. Family screening is possible, and effective 
intervention is available. Making the diagnosis early will 
prevent many premature deaths. the treatment of FH is 
not difficult and funding is often the largest obstacle to 
overcome initially, followed by the challenge of keeping the 
patient on treatment. 
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